AP NEWS

Cancer Cachexia Drug Development Pipeline Study, H1 2018 - ResearchAndMarkets.com

June 12, 2018

DUBLIN--(BUSINESS WIRE)--Jun 12, 2018--The “Cancer Cachexia: Drug Development Pipeline Study, H1 2018” report has been added to ResearchAndMarkets.com’s offering.

Cancer Cachexia pipeline comprises of 17 drugs under development as of March 2018. Of these, 1 drug is in Phase 1 and 4 drugs in phase 2 with 1 drug in Phase 3. Further, 10 drugs are in Pre-clinical stage and 1 drug is in research phase.

26 companies are developing the pipeline for Cancer Cachexia. Of this, Helsinn Healthcare, S.A has the most advanced stage drug in pipeline. Ghrelin receptor is the most targeted area for most compounds.

No compounds have been awarded orphan drug status for PAH. The market is estimated to be around $2 billion. While Anorexia refers to loss of appetite, the term Cachexia corresponds to weight loss including lean body mass and fat.

Around 5 million people are estimated to be affected by Anorexia/Cachexia and most of the patients have a short survival time. Further, these patients react poorly against chemotherapy treatments. Body composition changes are also observed in the patients including muscle wasting and lean tissue decrease.

The most comprehensive pipeline review Cancer Cachexia-Drug Development Pipeline Study provides in-depth analysis and update information on Cancer Cachexia pipeline drugs. Current status of all the drugs in the Cancer Cachexia pipeline is provided in the research work.

Further, the Cancer Cachexia report identifies aspects important in modifying industry market scenarios, increasing opportunities and list of potential companies that impact the Cancer Cachexia industry.

Key Topics Covered:

1 Figures & Tables

2 Executive Summary

2.1 Disease Overview

2.2 Pipeline Snapshot

2.3 Pipeline Drugs By Phase

2.4 Pipeline Drugs By Company

2.5 Pipeline Drugs By Mechanism Of Action

3 Cancer Cachexia - Company Wise Pipeline Analysis

3.1 Abreos Biosciences, Inc.

3.2 Aavogen

3.3 Acacia Pharma

3.4 Aeterna Zentaris Inc.

3.5 Aveo Oncology

3.6 Energenesis Biomedical Co., Ltd

3.7 Extend Biosciences

3.8 Helsinn Healthcare, S.A

3.9 Incyte Corporation

3.10 Neomed

3.11 Ngm Biopharmaceuticals

3.12 Paradigm Biopharma

3.13 Raqualia Pharma

3.14 Stemmed Ltd

3.15 Tci Peptide Therapeutics

3.16 Viking Therapeutics

4 Cancer Cachexia Drug Snapshots

4.1 Cryptic-Fc

4.2 Apd209

4.3 Macimorelin

4.4 Ruxolitinib Phosphate

4.5 Av-380

4.6 Ip1510

4.7 Rq-00433412

4.8 Vk 5211

4.9 Anamorelin

4.10 Hm03

4.11 Avgn7

4.12 C188-9

4.13 Energi-F706

4.14 Ext 400-Ghrelin

4.15 Neo1940

4.16 Cancer Cachexia Therapeutic

4.17 Ngm120

5 Recent Developments In Cancer Cachexia Pipeline

5.1 Promising New Drug Development Could Help Treat Cachexia - April 2017

5.2 Potential Target For Treating Cancer Cachexia - October 2017

5.3 Scientists Block Cancer-Induced Cachexia In Preclinical Trials - October 2017

6 Appendix

For more information about this report visit https://www.researchandmarkets.com/research/mvtvjq/cancer_cachexia?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180612006439/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Drug Discovery,Oncology Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/12/2018 03:58 PM/DISC: 06/12/2018 03:58 PM

http://www.businesswire.com/news/home/20180612006439/en

AP RADIO
Update hourly